Enbrel var signifikant bedre end placebo på alle mål for sygdomsaktivitet (p < 0, 001), og responsen var den samme med og uden samtidig methotrexat behandling.
Enbrel was significantly better than placebo in all measures of disease activity (p < 0.001), and responses were similar with and without concomitant methotrexate therapy.